As stated in the Herceptin® (trastuzumab), Perjeta® (pertuzumab), and Kadcyla® (ado-trastuzumab emtansine) Package Inserts, Herceptin, Perjeta, and Kadcyla are classified under Pregnancy Category D. Herceptin, Perjeta, and Kadcyla can cause fetal harm when administered to a pregnant woman. In post-marketing reports, use of HERCEPTIN during pregnancy resulted in cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise women of the potential hazard to the fetus resulting from Herceptin exposure during pregnancy and provide contraception counseling to women of childbearing potential. Exposure to PERJETA can result in embryo-fetal death and birth defects. Studies in animals have resulted in oligohydramnios, delayed renal development, and death. Exposure to KADCYLA can result in embryo-fetal death or birth defects. Advise patients of these risks and the need for effective contraception. Please refer to the Herceptin, Perjeta and Kadcyla Package Inserts for full prescribing information including Boxed WARNINGS and additional safety information.